Wire · opportunities
How RP1 Plus Nivolumab Overcame Two CRLs to Win Approval in Melanoma
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 August 2026 · Fusion42 review
In August 2026, the FDA granted accelerated approval to RP1 plus nivolumab for the treatment of unresectable advanced melanoma after progression on PD-1–blocking antibody therapy, following a regulatory review involving 3 BLAs, 2 complete response letters, and an advisory committee vote.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now access a more complex FDA approval route that accepts single-arm trial data in melanoma after PD-1 failure. Expect faster approval paths if your treatment targets unmet patient needs with innovative immunotherapy.
◆ Coverage
1 source · 28 Aug 2026
◆ Related on Wire
◆ Topics